We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Smr3.5
Sermorelin Research
Too few graded studies
16 peer-reviewed studies
What the evidence says
Too few graded studies
Sermorelin doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality randomised trials published 1986–2026 with a typical study size of 19 participants.
Based on 16 studies · 10 RCTs · 214 total participants
Confidence
Moderate confidence
By outcome
Growth hormone axis & GH deficiency
Too few graded studies11 studies
Aging & GH-axis restorationMarketed for "anti-aging" via GH/IGF-1, but a longevity or healthspan benefit is unproven; only the GH-secretion mechanism is established. · Not established
Too few graded studies4 studies
Safety profile
Too few graded studies1 study
Steady research
2 studies in the last 5 years
198620062026
1RCT1993
Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH · Acta Paediatr Suppl (1993)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
Coutinho LFD et al. · The Journal of sports medicine and physical fitness (2026)
Anecdotal reports and widespread promotion on social media suggest growing uptake among recreational gym-goers, including younger individuals, but prevalence studies are lacking.
This represents a critical gap in current knowledge.
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks.
In plain English: We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.
Mendias CL, Awan TM. · Sports medicine (Auckland, N.Z.) (2026)
Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.
This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered.
We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance.
In plain English: GHRH administered as a once daily dose of 30 micrograms/kg GHRH-(1-29), s.c., was effective in increasing height velocity in GH-deficient children.
Thorner M, Rochiccioli P, Colle M, Lanes R, et al. · J Clin Endocrinol Metab (1996)
Multicenter open-label study of 110 previously untreated prepubertal GH-deficient children given 30 µg/kg/day GHRH(1-29) sc at bedtime for up to 1 year
Mean height velocity rose from 4.1 cm/yr at baseline to 7.2 cm/yr at 12 months; 74% rated good responders at 6 months
No adverse changes in glucose or excessive IGF-1 generation; overall well tolerated
In plain English: Administration of PEG-GHRH generated a clear increase in circulating GH compared with placebo... Some impairment of glucose tolerance was observed in the elderly following repeated administration.
Munafo A, Nguyen TX, Papasouliotis O, Lécuelle H, et al. · Eur J Endocrinol (2005)
Phase I randomized placebo-controlled trial of a PEGylated GHRH (designed to extend the short GHRH(1-29) half-life) in 12 young men and 20 elderly men/women
Subcutaneous dosing raised circulating GH and IGF-1 vs placebo; injection-site reactions were mild and transient
Repeated dosing in the elderly impaired glucose tolerance — a relevant safety signal for GH-axis stimulation